SJS Investment Consulting
PLX icon

SJS Investment Consulting’s Protalix BioTherapeutics PLX Stock Holding History

SJS Investment Consulting’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$533 Buy
193
+163
+543% +$406 ﹤0.01% 2728
2026
Q2 		$70 Buy
+30
New +$64 ﹤0.01% 2671

Other funds holding PLX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

SJS Investment Consulting's PLX Position: Q3 2026 in Review

SJS Investment Consulting increased its Protalix BioTherapeutics (PLX) stake by 543% in Q3 2026, buying an estimated $406 and bringing the position to 193 shares worth $533. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

SJS Investment Consulting first reported a position in PLX in Q2 2026 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • SJS Investment Consulting held 193 shares of Protalix BioTherapeutics worth $533 as of Q3 2026.
  • SJS Investment Consulting bought 163 Protalix BioTherapeutics shares in Q3 2026, an estimated $406.
  • Protalix BioTherapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2728 holding.
  • SJS Investment Consulting first reported a position in Protalix BioTherapeutics in Q2 2026 and has held it in 2 quarters since.
  • 48 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.